{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T07:54:42Z","timestamp":1725954882158},"reference-count":75,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"DOI":"10.1182\/asheducation-2015.1.286","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"286-293","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Novel combination approaches for myeloma"],"prefix":"10.1182","volume":"2015","author":[{"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"8","key":"2019111703332996500_B1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W","article-title":"Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479","volume":"79","author":"Oken","year":"1997","journal-title":"Cancer"},{"issue":"9758","key":"2019111703332996500_B2","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","journal-title":"Lancet"},{"issue":"24","key":"2019111703332996500_B3","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703332996500_B4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111703332996500_B5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"36","key":"2019111703332996500_B6","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111703332996500_B7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e3181c51cd4","article-title":"The importance of complete response in outcomes in myeloma","volume":"15","author":"Nooka","year":"2009","journal-title":"Cancer J"},{"issue":"19","key":"2019111703332996500_B8","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood-2010-03-275800","article-title":"Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone","volume":"116","author":"Harousseau","year":"2010","journal-title":"Blood"},{"issue":"30","key":"2019111703332996500_B9","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111703332996500_B10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"34","key":"2019111703332996500_B11","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703332996500_B12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma","volume":"21","author":"Vij","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2019111703332996500_B13","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111703332996500_B14","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111703332996500_B15","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111703332996500_B16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2014-05-576256","article-title":"Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction\/consolidation therapy for newly diagnosed multiple myeloma","volume":"125","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111703332996500_B17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111703332996500_B18","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111703332996500_B19","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.197.197","article-title":"Superior efficacy of VTD over VCD as induction therapy for autotransplantation-eligible, newly diagnosed, myeloma patients","volume":"124","author":"Cavo","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2019111703332996500_B21","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111703332996500_B22","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111703332996500_B23","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II Study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111703332996500_B24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2011-02-334755","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1\/2 Multiple Myeloma Research Consortium trial","volume":"118","author":"Jakubowiak","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111703332996500_B25","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111703332996500_B26","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.336.336","article-title":"Lenalidomide, bortezomib, and dexamethasone (rvd) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): results of a phase 1 study","volume":"120","author":"Kaufman","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.33.33","article-title":"Phase I\/Ib trial of the efficacy and safety of combination therapy with lenalidomide\/bortezomib\/dexamethasone (RVD) and panobinostat in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"124","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2019111703332996500_B28","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111703332996500_B29","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"2019111703332996500_B30","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111703332996500_B31","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703332996500_B32","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2019111703332996500_B33","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171\u2013006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.202.202","article-title":"A phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed\/refractory multiple myeloma (R\/R MM): updated results","volume":"120","author":"Richardson","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B35","article-title":"Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma: data from a dose-escalation phase I\/II study","volume":"120","author":"Plesner","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"2019111703332996500_B36","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood.V122.21.1969.1969","article-title":"MM-005: a phase 1 trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V122.21.690.690","article-title":"Phase I\/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed\/refractory multiple myeloma","volume":"122","author":"Shah","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.V124.21.176.176","article-title":"An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma","volume":"124","author":"Moreau","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2019111703332996500_B39","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005\u201304 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111703332996500_B40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"2019111703332996500_B41","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111703332996500_B42","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"issue":"16","key":"2019111703332996500_B43","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-cs1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703332996500_B44","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.V122.21.1982.1982","article-title":"Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520 + carfilzomib (Car) in patients with relapsed and\/or refractory multiple myeloma (RRMM)","volume":"122","author":"Shah","year":"2013","journal-title":"Blood"},{"key":"2019111703332996500_B45","article-title":"Phase I study of combination of carfilzomib ad panabinostat for patients with relapsed and refractory myeloma: a multicenter MMRC clinical trial","author":"Kaufman"},{"issue":"21","key":"2019111703332996500_B46","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1182\/blood.V122.21.1937.1937","article-title":"A single-arm, open-label, multi-center phase I\/II study of the combination of panobinostat and carfilzomib in patients (pts) with relapsed or relapse\/refractory multiple myeloma (MM)","volume":"122","author":"Berdeja","year":"2013","journal-title":"Blood"},{"issue":"S1","key":"2019111703332996500_B47","first-page":"119","article-title":"VANTAGE 095: final results from a global, single-arm, phase 2b trial of vorinostat in combination with bortezomib in salvage multiple myeloma patients","volume":"97","author":"Siegel","year":"2012","journal-title":"Eur Hematol Assoc"},{"issue":"11","key":"2019111703332996500_B48","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"key":"2019111703332996500_B49","article-title":"Panorama 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma","volume":"32","author":"Richardson","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"issue":"21","key":"2019111703332996500_B50","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood.V122.21.759.759","article-title":"ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma (MM)","volume":"122","author":"Raje","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3190.3190","article-title":"ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and dexamethasone (dex), is well tolerated without dose limiting toxicity (DLT) in patients (Pts) With multiple myeloma (MM) at doses demonstrating biologic activity: interim results of a phase 1b trial","volume":"122","author":"Yee","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B52","article-title":"The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study","volume":"120","author":"Shah","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"2019111703332996500_B53","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood.V122.21.1938.1938","article-title":"A phase 1 study of ARRY-520 with bortezomib (BTZ) and dexamethasone (dex) in relapsed or refractory multiple myeloma (RRMM)","volume":"122","author":"Chari","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B54","article-title":"Prolonged survival and improved response rates with ARRY-520 in relapsed\/refractory multiple myeloma (RRMM) patients with low \u03b1-1 acid glycoprotein (AAG) levels: results from a phase 2 study","volume":"122","author":"Lonial","year":"2013","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"2019111703332996500_B55","first-page":"283","article-title":"Novel AKT inhibitor afuresertib in combination with bortezomib and dexamethasone demonstrates favorable safety profile and significant clinical activity in patients with relapsed\/refractory multiple myeloma","volume":"122","author":"Voorhees","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B56","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1182\/blood.V124.21.4773.4773","article-title":"Selinexor demonstrates marked synergy with dexamethasone (Sel-Dex) in preclinical models and in patients with heavily pretreated refractory multiple myeloma (MM)","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"2019111703332996500_B57","article-title":"Phase II study of daratumumab (DARA) monotherapy in patients with \u22653 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius)","volume":"33","author":"Lonial","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"issue":"21","key":"2019111703332996500_B58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V124.21.84.84","article-title":"Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma","volume":"124","author":"Plesner","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111703332996500_B59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111703332996500_B60","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111703332996500_B61","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2019111703332996500_B62","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111703332996500_B63","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood.V122.21.4607.4607","article-title":"Pilot study of regulatory T cell depletion in the setting of autologous stem cell transplantation for multiple myeloma","volume":"122","author":"Keudell","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B64","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1182\/blood.V124.21.4737.4737","article-title":"Initial results of a phase 1\/2a, dose escalation study of PVX-410 multi-peptide cancer vaccine in patients with smoldering multiple myeloma (SMM)","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B65","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.V122.21.1943.1943","article-title":"Phase I\/II trial of immucin a Pan HLA, anti-MUC1 signal peptide vaccine, in multiple myeloma patients with residual disease or progression following autologous stem cell transplantation","volume":"122","author":"Carmon","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111703332996500_B66","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov"},{"issue":"8","key":"2019111703332996500_B67","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"16","key":"2019111703332996500_B68","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B69","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/blood.V124.21.3486.3486","article-title":"A phase II, single-center, open-label study of oral panobinostat in combination with lenalidomide and weekly dexamethasone in patients with multiple myeloma","volume":"124","author":"Chari","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111703332996500_B70","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B71","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1182\/blood.V124.21.4766.4766","article-title":"Velcade, Thalidomide, dexamethasone and panobinostat (VTD-P) for patients with relapsed and relapsed\/ refractory myeloma: preliminary results of the Muk-Six phase I\/IIa trial","volume":"124","author":"Popat","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111703332996500_B72","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111703332996500_B73","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1182\/blood.V120.21.4082.4082","article-title":"Phase 1 study of the novel kinesin spindle protein inhibitor aRRY-520 + carfilzomib in patients with relapsed and\/or refractory multiple myeloma","volume":"120","author":"Shah","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111703332996500_B74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V124.21.32.32","article-title":"Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: a Multiple Myeloma Research Consortium (MMRC) clinical trial","volume":"124","author":"Kaufman","year":"2014","journal-title":"Blood"},{"key":"2019111703332996500_B75","article-title":"A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and\/or refractory multiple myeloma (MM)","volume":"32","author":"Vesole","year":"2014","journal-title":"ASCO Meeting Abstracts"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/286\/1250533\/bep00115000286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/286\/1250533\/bep00115000286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:33:46Z","timestamp":1573979626000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/286\/20693\/Novel-combination-approaches-for-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.286","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}